THE CHILDREN'S HOSPITAL OF PHILADELPHIA NON PROFIT ORG

Their core work

The Children's Hospital of Philadelphia (CHOP) is one of the world's leading pediatric academic medical centers, combining clinical care with research in rare childhood diseases and pediatric oncology. In H2020, CHOP contributed as a specialist partner — bringing access to pediatric patient populations, disease-specific biological expertise, and clinical research infrastructure that European university teams cannot replicate in-house. Their two projects reveal two distinct research competencies: deep mechanistic work on lysosomal disorders (rare genetic diseases), and applied digital health work where clinical data from real pediatric cancer patients feeds computational models. For any consortium needing credible pediatric clinical grounding, CHOP is among a very small number of institutions globally that can provide it.

What they specialise in

How they've shifted over time

CHOP entered H2020 through rare disease basic research: LysoMod (2017) focused on lysosomal biology, lipid metabolism, and genetic modifiers — bench-level science. By 2019, their second project (iPC) marked a clear pivot toward digital and computational pediatric medicine, with keywords shifting to virtual patients, cloud computing, and data harmonization. The direction is consistent with a broader trend in academic medical centers: moving from disease mechanism discovery toward clinical data-driven precision medicine tools that work at scale.

CHOP is moving from foundational disease biology toward computational and data-driven pediatric medicine — making them an increasingly relevant partner for digital health consortia that need credible clinical pediatric data and validation capacity.

How they like to work

CHOP has never led an H2020 project — they join as a specialist partner or third party, contributing targeted expertise rather than overall project coordination. Both of their projects were large international consortia (35 unique partners across 17 countries combined), which indicates that CHOP is brought in specifically for what they uniquely offer — pediatric clinical access and disease expertise — rather than for general research capacity. This is a typical pattern for major clinical institutions: high-value, defined contributor role within broader scientific collaborations.

Despite only 2 H2020 projects, CHOP has worked with 35 unique consortium partners across 17 countries — reflecting participation in large, well-connected European research networks. Their partners are predominantly European, with CHOP serving as the transatlantic clinical anchor in both consortia.

What sets them apart

CHOP is one of the few US-based pediatric hospitals with active H2020 participation, making them a rare transatlantic bridge for European research consortia that need access to large, well-documented pediatric patient cohorts and clinical validation environments. They are consistently ranked among the top children's hospitals in the world, which means their name on a consortium application carries scientific credibility that is difficult to substitute. For projects targeting childhood diseases — rare genetic disorders or pediatric cancers — CHOP is a uniquely valuable clinical partner that most European institutions cannot match domestically.

Highlights from their portfolio

• iPC
  The only funded project (EUR 175,652) and the most technically ambitious — combining cloud computing, virtual patient modeling, and multi-country clinical data to tackle precision medicine in pediatric cancer, a combination of digital and health expertise rarely seen in a single H2020 project.
• LysoMod
  A MSCA-RISE mobility and exchange project covering lysosomal biology and lipidomics — CHOP's role here as a transatlantic partner in a rare disease research network highlights their niche depth in genetic metabolic disorders affecting children.